Depuydt Pieter O, Benoit Dominique D, Vandewoude Koenraad H, Decruyenaere Johan M, Colardyn Francis A
Department of Intensive Care, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
Chest. 2004 Oct;126(4):1299-306. doi: 10.1378/chest.126.4.1299.
The survival rate of patients with a hematologic malignancy requiring mechanical ventilation (MV) in the ICU has improved over the last few decades. The objective of this study was to identify the factors affecting the in-hospital mortality of these particular patients, and to assess whether the use of noninvasive positive pressure ventilation (NPPV) was protective in our study population.
We retrospectively collected variables in 166 consecutive patients with hematologic malignancies who had acute respiratory failure (ARF) requiring MV, and identified factors obtained within 24 h of ICU admission affecting in-hospital mortality in univariate and multivariate stepwise logistic regression analyses. The effect of NPPV on mortality was assessed using a pair-wise matched exposed-unexposed analysis.
The mean simplified acute physiology score (SAPS) II was 58.9. The in-hospital mortality rate was 71%. In a multivariate logistic regression analysis, the in-hospital mortality rate was predicted by increasing severity of illness, as measured by SAPS II (odds ratio [OR] per point of increase, 1.07; 95% confidence interval [CI], 1.04 to 1.11) and a diagnosis of acute myelogenous leukemia (OR, 2.73; 95% CI, 1.05 to 7.11). Female sex (OR, 0.36; 95% CI, 0.16 to 0.82), endotracheal intubation (ETI) within 24 h of ICU admission (OR, 0.29; 95% CI, 0.11 to 0.78), and recent bacteremia (defined as blood cultures positive for bacteria < 48h before or < 24h after ICU admission) [OR, 0.22; 95% CI, 0.08 to 0.61] were associated with a lower mortality rate. Twenty-seven patients who received NPPV were matched for SAPS II (+/- 3) with 52 patients who required immediate ETI on a 1:2 basis. The crude in-hospital mortality rate was 65.4% in both groups.
Although the in-hospital mortality rate in hematologic patients who develop ARF remains high, the reluctance to intubate and start treatment with invasive MV in this population is unjustified, especially when bacteremia has precipitated ICU admission.
在过去几十年中,入住重症监护病房(ICU)且需要机械通气(MV)的血液系统恶性肿瘤患者的生存率有所提高。本研究的目的是确定影响这些特定患者院内死亡率的因素,并评估在我们的研究人群中使用无创正压通气(NPPV)是否具有保护作用。
我们回顾性收集了166例连续的患有急性呼吸衰竭(ARF)且需要MV的血液系统恶性肿瘤患者的变量,并在单因素和多因素逐步逻辑回归分析中确定了ICU入院后24小时内获得的影响院内死亡率的因素。使用配对匹配的暴露-未暴露分析评估NPPV对死亡率的影响。
简化急性生理学评分(SAPS)II的平均值为58.9。院内死亡率为71%。在多因素逻辑回归分析中,院内死亡率可通过疾病严重程度的增加来预测,以SAPS II衡量(每增加一分的比值比[OR]为1.07;95%置信区间[CI]为1.04至1.11)以及急性髓系白血病的诊断(OR为2.73;95%CI为1.05至7.11)。女性(OR为0.36;95%CI为0.16至0.82)、ICU入院后24小时内进行气管插管(ETI)(OR为0.29;95%CI为0.11至0.78)以及近期菌血症(定义为ICU入院前<48小时或入院后<24小时血培养细菌阳性)[OR为0.22;95%CI为0.08至0.61]与较低的死亡率相关。27例接受NPPV的患者与52例需要立即进行ETI的患者按1:2的比例进行SAPS II(±3)匹配。两组的粗院内死亡率均为65.4%。
尽管发生ARF的血液系统疾病患者的院内死亡率仍然很高,但在这一人群中不愿进行插管并开始有创MV治疗是不合理的,尤其是当菌血症促使患者入住ICU时。